Italian MS Experts Reach Consensus on Personalized Multiple Sclerosis Treatment
Delphi study of 166 Italian neurologists establishes guidelines for individualized MS therapy based on patient needs and drug characteristics.
Summary
A comprehensive Delphi consensus study involving Italian multiple sclerosis experts evaluated 166 statements about personalized MS treatment approaches. The panel reached consensus on 70% of statements, emphasizing the central role of neurologists in treatment decisions, the importance of patient involvement in therapeutic choices, and the value of high-efficacy disease-modifying therapies like cladribine and anti-CD20 treatments. The study provides a roadmap for optimizing individualized MS care while addressing patient quality of life and caregiver burden.
Detailed Summary
Multiple sclerosis treatment has evolved dramatically with the introduction of numerous disease-modifying therapies (DMTs), creating opportunities for truly personalized care. However, ensuring equitable access to optimized, individualized treatment strategies remains a challenge, particularly in Italy where regional disparities exist.
This landmark Delphi consensus study brought together leading Italian neurologists specializing in MS to evaluate 166 statements covering personalized therapy approaches, patient involvement in decision-making, treatment flexibility, and therapeutic sequencing. The methodology followed established Delphi guidelines to achieve expert consensus on best practices for MS care.
The results revealed strong agreement among experts, with 116 statements (70%) reaching consensus - 68% positive and 2% negative. Key areas of consensus included the central role of neurologists in treatment evaluation, the critical importance of personalizing therapy to optimize effectiveness while reducing side effects, and the need to actively involve patients in therapeutic decisions to improve adherence and quality of life. Experts particularly endorsed high-efficacy DMTs like cladribine and anti-CD20 therapies (ocrelizumab, ofatumumab) for their efficacy and convenient administration schedules.
The study highlighted specific considerations for different patient populations, including women of reproductive age planning pregnancy and patients with comorbidities. Experts emphasized that treatment choices should account for patients' life circumstances, including work, travel, and family planning needs. The consensus also stressed the importance of discussing prognosis at diagnosis and providing comprehensive information to support informed decision-making.
These findings provide a evidence-based framework for standardizing personalized MS care across Italy while maintaining flexibility for individual patient needs. The consensus represents a significant step toward addressing the treatment disparities identified in Italy's 2023 MS Barometer report.
Key Findings
- 70% of treatment statements reached expert consensus, with strong support for personalized therapy approaches
- High-efficacy DMTs like cladribine and anti-CD20 therapies received highest endorsement for convenience and efficacy
- Patient involvement in treatment decisions deemed essential for improving adherence and quality of life
- Treatment flexibility for work, travel, and family planning identified as critical patient need
- Neurologist's central role in therapy evaluation and patient communication strongly endorsed
Methodology
Delphi consensus methodology involving Italian MS expert panel evaluating 166 predefined statements across six treatment domains. Consensus defined as agreement among participating neurologists following established Delphi reporting guidelines.
Study Limitations
Study focused specifically on Italian healthcare context and expert opinions. Consensus represents expert judgment rather than clinical trial evidence. Some statements (30%) failed to reach consensus, indicating ongoing areas of uncertainty in MS treatment approaches.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.